newsFirst Hepatitis C treatment data demonstrating proof of principle with direct-acting antiviral-only therapy published18 January 2012 | By Bristol-Myers Squibb CompanyFull results from a Phase II clinical trial...
newsBristol-Myers Squibb begins tender offer to acquire Inhibitex, Inc.13 January 2012 | By Bristol-Myers Squibb CompanyBristol-Myers Squibb Company is commencing a cash tender offer to purchase all outstanding shares of common stock of Inhibitex...
newsBristol-Myers Squibb to acquire Inhibitex7 January 2012 | By Bristol-Myers SquibbBristol-Myers Squibb to acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger...
newsSimcere and Bristol-Myers Squibb enter innovative partnership to develop cardiovascular compound15 December 2011 | ByThe companies have expanded the strategic partnership formed last year...
newsBristol-Myers Squibb enters clinical collaboration agreement with Tibotec Pharmaceuticals2 December 2011 | By Bristol-Myers Squibb CompanyPhase II combination study in patients chronically infected with Hepatitis C...
newsFDA accepts ELIQUIS® (apixaban) New Drug Application for review29 November 2011 | By Bristol-Myers Squibb CompanyBristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. FDA has accepted for review a NDA for ELIQUIS® (apixaban)...
newsKOMBOGLYZE™ receives marketing authorisation in the European Union for adult patients with Type 2 diabetes29 November 2011 | By AstraZenecaThe European Commission has granted marketing authorisation for KOMBOGLYZE™...
newsONGLYZA® (saxagliptin) approved for use in Europe as combination therapy with insulin in adults with type 2 diabetes28 November 2011 | By Bristol-Myers Squibb CompanyThe European Commission has approved ONGLYZA® (saxagliptin)...
newsNew data presented on Phase 3 trial of ELIQUIS® (apixaban)13 November 2011 | By PfizerBristol-Myers Squibb Company and Pfizer Inc. announced the results of the Phase 3 ADOPT trial...
news12-week on-treatment results from large Phase IIb study (COMMAND-1) of Bristol-Myers Squibb’s NS5A inhibitor daclatasvir support anti-HCV activity and safety profile observed in earlier studies8 November 2011 | By Bristol-Myers Squibb CompanyStudy evaluated daclatasvir as add-on to peginterferon alfa/ribavirin (alfa/RBV)...
newsFDA approves ERBITUX® (cetuximab) for first-line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil7 November 2011 | By Bristol-Myers Squibb CompanyERBITUX now approved for five indications across two tumor types...
newsASLAN Pharmaceuticals and Bristol-Myers Squibb enter innovative partnership3 November 2011 | By Bristol-Myers Squibb CompanyInnovative strategic partnership to license and develop investigational oncology compound...
newsBristol-Myers Squibb and Gilead Sciences announce licensing agreement26 October 2011 | By Bristol-Myers Squibb CompanyLicensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination...
newsUS FDA extends action date for dapagliflozin by three months26 October 2011 | By AstraZenecaUS FDA has extended the action date for dapagliflozin for the treatment of type 2 diabetes by three months...
newsAmgen appoints Anthony Hooper Executive Vice President Global Commercial Operations19 October 2011 | By AmgenAmgen appoints Anthony Hooper as Executive VP, Global Commercial Operations...
